FDA Table 2 – Baseline Demographic and Clinical Characteristics, Safety Population, Pooled Analyses
FDA Table 3 – Patient Screening and Enrollment, Trials A and B
FDA Table 5 – Duration of Treatment Exposure, Safety Population, Pooled Analyses
FDA Table 6 – Overview of Adverse Events, Safety Population, Pooled Analyses
FDA Table 8 – All Individual Patient Deaths, Safety Population, Pooled Analyses
---
title: Template Library Index
---
------------------------------------------------------------------------
### **FDA Tables**
- [FDA Table 2 -- Baseline Demographic and Clinical Characteristics, Safety Population, Pooled Analyses](table-templates/template-table_02.qmd)
- [FDA Table 3 -- Patient Screening and Enrollment, Trials A and B](table-templates/template-table_03.qmd)
- [FDA Table 4 -- Patient Disposition, Pooled Analyses](table-templates/template-table_04.qmd)
- [FDA Table 5 -- Duration of Treatment Exposure, Safety Population, Pooled Analyses](table-templates/template-table_05.qmd)
- [FDA Table 6 -- Overview of Adverse Events, Safety Population, Pooled Analyses](table-templates/template-table_06.qmd)
- [FDA Table 7 -- Deaths, Safety Population, Pooled Analyses](table-templates/template-table_07.qmd)
- [FDA Table 8 -- All Individual Patient Deaths, Safety Population, Pooled Analyses](table-templates/template-table_08.qmd)
- [FDA Table 9 -- Patients With Serious Adverse Events by System Organ Class and Preferred Term, Safety Population, Pooled Analyses](table-templates/template-table_09.qmd)
- [FDA Table 10 -- Patients With Serious Adverse Events by System Organ Class and FDA Medical Query (Narrow), Safety Population, Pooled Analyses](table-templates/template-table_10.qmd)
- [FDA Table 11 -- Patients with FDA Medical Query (Narrow) Leading to Treatment Discontinuation, Safety Population, Pooled Analyses](table-templates/template-table_11.qmd)
- [FDA Table 12 -- Patients With Adverse Events Leading to Treatment Discontinuation by System Organ Class and Preferred Term, Safety Population, Pooled Analyses](table-templates/template-table_12.qmd)
- [FDA Table 13 -- Patients With Common Adverse Events Occurring at >=X% Frequency, Safety Population, Pooled Analyses](table-templates/template-table_13.qmd)
- [FDA Table 14 -- Patients With Adverse Events by System Organ Class and FDA Medical Query, Safety Population, Pooled Analyses](table-templates/template-table_14.qmd)
- [FDA Table 15 -- Patients With Adverse Events by Male-Specific FDA Medical Query (Narrow) and Preferred Term, Male Safety Population, Pooled Analyses](table-templates/template-table_15.qmd)
- [FDA Table 16 -- Patients With Adverse Events by Male-Specific FDA Medical Query (Broad) and Preferred Term, Male Safety Population, Pooled Analyses](table-templates/template-table_16.qmd)
- [FDA Table 17 -- Patients With Adverse Events by Female-Specific FDA Medical Query (Narrow) and Preferred Term, Female Safety Population, Pooled Analyses](table-templates/template-table_17.qmd)
- [FDA Table 18 -- Patients With Adverse Events by Female-Specific FDA Medical Query (Broad) and Preferred Term, Female Safety Population, Pooled Analyses](table-templates/template-table_18.qmd)
- [FDA Table 20 -- Adverse Events of Special Interest Assessment, Safety Population, Pooled Analysis (or Trial X)](table-templates/template-table_20.qmd)
- [FDA Table 21 -- Overview of Serious Adverse Events1 by Demographic Subgroup, Safety Population, Pooled Analysis (or Trial X)](table-templates/template-table_21.qmd)
- [FDA Table 22 -- Overview of Adverse Events1 by Demographic Subgroup, Safety Population, Pooled Analysis (or Trial X)](table-templates/template-table_22.qmd)
- [FDA Table 32 -- Percentage of Patients With Maximum Diastolic Blood Pressure by Category of Blood Pressure Postbaseline, Safety Population, Pooled Analysis](table-templates/template-table_32.qmd)
- [FDA Table 33 -- Percentage of Patients Meeting Specific Hypotension Levels Postbaseline, Safety Population, Pooled Analysis](table-templates/template-table_33.qmd)
- [FDA Table 34 -- Patients With Serious Adverse Events by System Organ Class, FDA Medical Query (Narrow), and Preferred Term, Safety Population, Pooled Analysis (or Trial X)](table-templates/template-table_34.qmd)
- [FDA Table 35 -- Patients With Adverse Events by System Organ Class, Safety Population, Pooled Analysis (or Trial X)](table-templates/template-table_35.qmd)
- [FDA Table 36 -- Patients With Adverse Events by System Organ Class and Preferred Term, Safety Population, Pooled Analysis (or Trial X)](table-templates/template-table_36.qmd)
- [FDA Table 38 -- Patients With Adverse Events by System Organ Class, FDA Medical Query (Broad) and Preferred Term, Safety Population, Pooled Analysis (or Trial X)](table-templates/template-table_38.qmd)
------------------------------------------------------------------------
### **FDA Figures**
- [FDA Figure 1 -- Time to Permanent Discontinuation of Study Drug, Safety Population, Pooled Analyses](figure-templates/template-fig_01.qmd)
- [FDA Figure 2 -- Time to Last Follow Up, Safety Population, Pooled Analyses](figure-templates/template-fig_02.qmd)
- [FDA Figure 3 -- Figure 3. Time to Adverse Event Leading to Treatment Discontinuation, Safety Population, Trial X](figure-templates/template-fig_03.qmd)
- [FDA Figure 14 -- Mean and 95% Confidence Interval of Systolic Blood Pressure Over Time by Treatment Arm, Safety Population, Trial X](figure-templates/template-fig_14.qmd)